# US 2024/0130983 A1 · Compounds for treating coronavirus infection

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0130983 A1
- Document ID: US20240130983A1
- Status: Published application
- Kind: A1
- Application number: 18/393,798
- Filed: 2023-12-22
- Published: 2024-04-25
- Earliest claimed: 2020-02-14
- Assignees: NLC Pharma Ltd
- Applicants: NLC Pharma Ltd
- Inventors: Dorit ARAD
- Web page: https://patentgrep.com/patent/US20240130983A1

## CPC

- A61K 31/122: having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
- C07C 50/32: the quinoid structure being part of a condensed ring system having two rings
- A61K 9/0053: {Mouth and digestive tract, i.e. intraoral and peroral administration}
- A61K 9/0095: {Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches (A61K9/0007 takes precedence; eatable gels or foams A61K9/0056; oral mucosa adhesive forms A61K9/006)}
- A61K 9/127: Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
- A61K 9/2009: {Inorganic compounds}
- A61K 9/2013: {Organic compounds, e.g. phospholipids, fats}
- A61K 9/2018: {Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates}
- A61K 9/2054: {Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose}
- A61K 9/2095: {Tabletting processes}
- A61K 9/282: {Organic compounds, e.g. fats}
- A61K 9/2833: {Organic macromolecular compounds}
- A61K 9/4833: {Encapsulating processes; Filling of capsules (mechanical aspects A61J3/07)}
- A61K 9/4858: {Organic compounds}
- A61K 9/4866: {Organic macromolecular compounds}
- A61K 31/198: Alpha-amino acids, e.g. alanine or edetic acid [EDTA] (betaine A61K31/205; proline A61K31/401; tryptophan A61K31/405; histidine A61K31/4172; peptides not degraded to individual amino acids A61K38/00)
- A61K 31/222: with compounds having aromatic groups, e.g. dipivefrine, ibopamine
- A61K 31/381: having five-membered rings
- A61K 31/40: having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K 31/422: not condensed and containing further heterocyclic rings
- A61K 31/433: Thidiazoles
- A61K 31/454: containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
- A61K 31/513: having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
- A61K 31/536: ortho- or peri-condensed with carbocyclic ring systems
- A61K 36/30: Boraginaceae (Borage family), e.g. comfrey, lungwort or forget-me-not
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 31/14: for RNA viruses
- A61K 2236/51: Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C07C: ACYCLIC OR CARBOCYCLIC COMPOUNDS
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Described herein are compounds of Formula I: wherein R1-R6 are as described herein, for use in the treatment of a coronavirus infection; a method of inhibiting a coronavirus 3CL protease, by contacting the 3CL protease with a compound of Formula I; as well as methods pharmaceutical composition comprising a compound of Formula I and at least one phospholipid, wherein a weight ratio of the phospholipid(s) to the compound in the composition is in a range of from 10:1 to 1:10. Further described herein is a method of treating a coronavirus infection in a subject in need thereof, by administering to the subject at least one compound that exhibits at least two of: inhibition of an activity of a 3CL protease of the coronavirus; inhibition of inflammation in the subject; and inhibition of autophagy in the subject.

## Claims

### Claim 1

A pharmaceutical composition comprising:
a compound represented by Formula I:
wherein R1-R6 are each independently selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl, heteroalicyclic, halo, hydroxy, alkoxy, aryloxy, thiohydroxy, thioalkoxy, thioaryloxy, sulfinyl, sulfonyl, sulfonate, sulfate, cyano, nitro, azide, phosphonyl, phosphinyl, carbonyl, thiocarbonyl, a urea group, a thiourea group, O-carbamyl, N-carbamyl, O-thiocarbamyl, N-thiocarbamyl, S-thiocarbamyl, C-amido, N-amido, C-carboxy, O-carboxy, sulfonamido, guanyl, guanidinyl, hydrazine, hydrazide, thiohydrazide, and amino, or alternatively, R1 and R2 together form a five- or six-membered aromatic or aliphatic ring,
and further comprising:
a) at least one phospholipid, wherein a weight ratio of said at least one phospholipid to said compound in the composition is in a range of from 10:1 to 1:10,
and/or
b) liposomes.

### Claim 2 (depends on 1)

The pharmaceutical composition of claim 1, comprising at least one phospholipid, wherein a weight ratio of said at least one phospholipid to said compound in the composition is in a range of from 10:1 to 1:10.

### Claim 3 (depends on 1)

The pharmaceutical composition of claim 1, comprising liposomes.

### Claim 4 (depends on 1)

The pharmaceutical composition of claim 1, wherein at least one, or each, of R3 and R6 is OH.

### Claim 5 (depends on 1)

The pharmaceutical composition of claim 1, wherein R1 is represented by:
wherein R′1, R″1, and R7 are each independently selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, heteroalicyclic, and carbonyl.

### Claim 6 (depends on 5)

The pharmaceutical composition of claim 5, wherein R7 is a saccharide moiety or a peptide moiety, or wherein R7 is hydrogen or carbonyl.

### Claim 7 (depends on 1)

The pharmaceutical composition of claim 1, wherein the compound is shikonin or a glycoside of shikonin, or an ester thereof.

### Claim 8 (depends on 1)

The pharmaceutical composition of claim 1, further comprising at least one additional active agent selected from the group consisting of a vitamin, N-acetyl cysteine, an anticoagulant, an anti-inflammatory agent, an antipyretic agent, an antiviral agent, and a protease inhibitor.

### Claim 9 (depends on 8)

The pharmaceutical composition of claim 8, wherein said protease inhibitor is capable of inhibiting 3C protease and/or a 3CL protease.

### Claim 10 (depends on 1)

The pharmaceutical composition of claim 1, capable of at least one of:
(i) inhibiting an activity of a 3CL protease;
(ii) inhibiting inflammation; and
(iii) inhibiting autophagy.
